• Home
  • EMCrit-RACC
  • PulmCrit
  • IBCC
  • EMNerd
  • Tox & Hound
  • About
    • About EMCrit
    • About PulmCrit
    • EMCrit FAQ
    • Subscription Options
  • Contact Us

PulmCrit (EMCrit)

Online Medical Education on Emergency Department (ED) Critical Care, Trauma, and Resuscitation

  • About PulmCrit
  • Genius General Hospital
  • PulmCrit TOC
  • IBCC TOC
  • IBCC Podcast
You are here: Home / PULMCrit / PulmCrit- Intravenous olanzapine: Faster than IM olanzapine, safer than IV haloperidol?

PulmCrit- Intravenous olanzapine: Faster than IM olanzapine, safer than IV haloperidol?

February 1, 2016 by Josh Farkas 14 Comments

 reaper77Introduction with a case

An elderly woman was admitted to the ICU for COPD exacerbation requiring BiPAP.  Her COPD improved but she developed delirium.  She was increasingly agitated, attempting to remove her oxygen and intravenous lines.  She received 4 mg IV haloperidol, but continued to be agitated.  Eventually after titration to a total of 12 mg IV haloperidol she became somnolent.  At that point it was noted that despite her sleeping, she manifested myoclonic jerking of her extremities (a new finding).

What happened?  With hindsight, it is likely that she began experiencing akathisia as a side effect of the IV haloperidol used to sedate her (which caused worsening restlessness, agitation, and myoclonic jerking).  This is a potential pitfall of using haloperidol for treatment of agitation, because akathisia may actually exacerbate the patient’s agitation, leading to a vicious cycle involving further haloperidol administration.  Diagnosing akathisia in an agitated patient can be difficult.  How could this complication be avoided in the future? (1)

The evolution of intravenous olanzapine

Technically, haloperidol is not FDA-approved for intravenous use.  However, shortly after intramuscular haloperidol was released, physicians realized that it could be given intravenously.  Over time, IV haloperidol became widespread and accepted.

Olanzapine (ZYPREXA) seems to be undergoing a similar process.  Although olanzapine isn’t FDA-approved for intravenous administration, it is increasingly recognized that this is effective and safe.  For example, the “intramuscular” formulation of olanzapine has a neutral pH and contains substances which can be given intravenously (olanzapine, lactose, and tartrate – as in metoprolol tartrate).  IV olanzapine was initially utilized in Australia (Chan 2009, 2011).

The rationale for using IV olanzapine isn’t superior efficacy compared to haloperidol, but rather equivalent efficacy with fewer side effects (2).  What does the evidence show?

Efficacy of olanzapine for acute agitation

Efficacy of IM olanzapine

The efficacy of IM olanzapine has been investigated more thoroughly than IV olanzapine.  Five RCTs involving 613 patients have compared IM olanzapine versus IM haloperidol (Kishi 2015).  These studies either found that the two drugs were equally effective or that olanzapine was slightly more effective (depending on the relative doses utilized)(3).

Efficacy of IV olanzapinedroperidol

Chan 2013 performed a prospective RCT of agitated emergency department patients who received titrated open-label midazolam in addition to being randomized to receive one of three treatments: 5 mg IV olanzapine, 5 mg IV droperidol, or placebo.  Droperidol and olanzapine were equally effective.

Safety of olanzapine: Torsade de pointes?

It can be hard to determine whether a drug causes torsade de pointes (TdP), because this event is rare.  Several sources of evidence bear consideration:

HERG channel affinity

herg77The primary driver of drug-induced TdP is blockade of the HERG potassium channel involved in myocardial repolarization (Crumb 2006).  Drugs with a greater affinity for the HERG channel tend to cause more TdP.  As shown above, olanzapine's affinity for HERG channels is 6,000 times below haloperidol's affinity.  Additionally, a guinea pig model suggests that olanzapine tends to be less concentrated within myocardial tissue.

Typical therapeutic serum concentrations of olanzapine are 32-64 nM, which might correlate with a concentration of perhaps ~86-170 nM within the myocardium.  These concentrations are well below the half-maximal inhibitory concentration (IC-50) of 6,000 nM, predicting an absence of proarrhythmia (Titier 2004).

Animal models

mice550Ando 2007 studied the arrhythmic potential of intravenous risperidone or olanzapine in a canine model.  Risperidone caused prolongation of ventricular repolarization only at supra-therapeutic doses.  In contrast, intravenous olanzapine had minimal effects on repolarization even at very high doses (3 mg/kg; figure below).

Effect on QT interval in humans

qtch Although QT interval isn't perfect, it remains a clinically relevant measurement of how drugs affect cardiac repolarization.  Harrigan 2004 performed a prospective RCT comparing the effect of several antipsychotic agents on the QTc interval.  As shown, olanzapine had no effect on QTc interval (even at a dose of 20 mg/day).  Lack of effect on QTc has been validated by other studies (Lindborg 2003, Shafti 2014, Takeuchi 2014).

Case reports of TdP

Currently there is only one case report in the literature of a patient with TdP related to olanzapine (Huang 2014).  However, this woman also had cardiomyopathy status post placement of an implantable defibrillator, hypomagnesemia, and hypokalemia, making it impossible to establish causality between olanzapine and TdP.  Overall there is a notable absence of case reports of TdP.

Epidemiology

Population-wide correlations between antipsychotic use and sudden death yield conflicting results, without any consistent hierarchy of risk among different antipsychotics (Ray 2009, Danielsson 2016, Leonard 2013).  Due to confounding variables and contradictory results, no conclusions can be drawn from this data.

Bottom line on TdP

The best available evidence doesn’t reveal a risk of TdP due to olanzapine.  There is no indication for monitoring the QT interval in patients receiving olanzapine.

Safety of olanzapine: Extrapyramidal symptoms

Olanzapine causes fewer extrapyramidal symptoms than haloperidol.  This has been shown in RCTs comparing haloperidol vs. olanzapine administered via either oral (Tollefson 1997) or IM routes (Wright 2001, Breier 2002).

With haloperidol, intravenous use is associated with fewer extrapyramidal side effects compared to oral administration.  If the same relative reduction in extrapyramidal symptoms were true of IV olanzapine compared to oral olanzapine, it would suggest that IV olanzapine should have a very low rate of extrapyramidal symptoms.  One large study of IV olanzapine reported a 0.6% rate of akathisia and no dystonic reactions, consistent with this possibility (more on this study below; Martel 2015).

Other safety concerns?

Some concerns have been raised about over-sedation due from the combination of IM olanzapine with benzodiazepines.  However, the RCT by Chan 2013 discussed above reported no increase in adverse effects among 109 patients receiving IV olanzapine plus midazolam, compared to patients receiving placebo plus midazolam.  There was actually a trend towards increased desaturation in the placebo group, likely due to higher doses of midazolam required in the placebo group.

IV olanzapine may be safer than IM olanzapine, because IV olanzapine works faster, allowing it to be titrated accurately.  Alternatively, agitated patients who receive IM olanzapine may continue to receive several doses of benzodiazepine, before the olanzapine has taken effect.  When the IM olanzapine finally reaches peak effect, the combination of olanzapine plus several doses of benzodiazepine could cause over-sedation (“dose-stacking”).  Notably, the recommended starting dose of IM olanzapine is 10 mg, whereas most patients receiving IV olanzapine require only ~5 mg.  Thus, titrated doses of IV olanzapine may reduce the total dose administered.

boxMartel 2015 reported a retrospective cohort study examining side effects experienced by 713 patients who received IV olanzapine in the emergency department.  The only safety concern raised in this article were three intubations potentially related to olanzapine (adjacent box).  These intubations might have been required regardless of the choice of antipsychotic.  Overall this study is reassuring, since it represents a large pragmatic description of olanzapine use in acutely ill patients that failed to reveal any unexpected problems.

Pharmacoeconomics

Olanzapine is currently off-patent, but it may remain somewhat more expensive than haloperidol (4).  However, haloperidol is associated with costs of obtaining EKGs and more frequent treatment of extrapyramidal reactions (e.g. intravenous diphenhydramine).  Additionally, although TdP is rare, the cost of treating a single episode can be enormous.

Formal pharmacoeconomic analyses show that the primary determinant of the cost of managing an agitated patient is time: anything which prolongs the ED or ICU length of stay is expensive (e.g. one day in the ICU costs ~$3,000; Chan 2012).  This makes it unwise to choose a cheaper drug that may occasionally prolong length of stay.

Choosing: IV Olanzapine vs. IV Haloperidol?

Is IV olanzapine ready for prime time?  This boils down to a choice of the devil that we know (haloperidol) versus the devil that we don’t entirely know (olanzapine).  IV olanzapine is newer, so it is possible that additional side effects may emerge over time.  However, we already know that there are significant problems with IV haloperidol.

IV haloperidol can cause TdP.  Patients receiving this should be monitored with serial EKGs to minimize their risk.  However, in practice it may be impossible to obtain an EKG in an agitated patient.  Thus, compliance with recommended QT monitoring for IV haloperidol is extremely poor (Warnier 2015).  This represents a systemic source of risk to our patients.

The switch to olanzapine might be justifiable solely on the basis that we could spend less time checking EKGs and debating the damn QTc.  Humans have a limited capacity to make decisions and pay attention to details.  As discussed by Scott Weingart in the John Hinds Memorial Lecture, making too many decisions (even minor decisions) leads to decision fatigue.  Eliminating unnecessary decisions and interruptions could free up physicians and nurses to pay attention to more important problems.

Ultimately, weighing the known versus the unknown is a matter of judgment.  Some centers (e.g. Hennepin County Hospital) have already broadly adopted IV olanzapine.  Another approach might be to selectively use IV olanzapine for patients at higher risk of harm from haloperidol (e.g. patients with prolonged QT or patients who are too agitated to obtain an EKG).

Nuts and bolts: How to use IV olanzapine

For agitation, a reasonable dose appears to be 2.5-5 mg IV, repeated every 5-10 minutes to a maximal dose of 20mg (similar to IV droperidol).  Note that IV olanzapine appears to be roughly twice as powerful as haloperidol (e.g. 2.5-5 mg olanzapine may be equivalent to ~5-10 mg haloperidol).  As with any sedative, using lower doses and increasing the time interval between doses will reduce the risk of over-sedation.

Returning to the case

Akathisia is 3-5 times less common with olanzapine compared to haloperidol (Tollefson 1997, Kishi 2015).  Therefore, using IV olanzapine in the case described above might have avoided this complication entirely.  Alternatively, it is possible that even if did occur with IV olanzapine, it might have been less severe.

bullet21

  • Intravenous use of haloperidol is not FDA-approved, but is widely utilized and accepted in the literature.
  • Recent studies suggest that olanzapine can also be given intravenously, even though it is labeled only for intramuscular use.
  • One RCT showed that IV olanzapine was as effective as IV droperidol.
  • Olanzapine does not cause torsade de pointes, nor does it require monitoring with serial EKGs.
  • The rate of extrapyramidal side effects with olanzapine is lower than with haloperidol.
  • Intravenous olanzapine may be an attractive alternative to intravenous haloperidol, particularly among patients at risk for arrhythmia.

expert-commentTo get the perspective of a clinician experienced with using IV olanzapine, I reached out to Dr. Marc Martel.  He is an Associate Professor of Emergency Medicine at Hennepin County Medical Center, sedation guru, and author of the recent paper discussed above in Academic Emergency Medicine. These are his comments:

The “right” answer is never hoping or waiting for an acutely agitated patient to calm down.  Working night shifts exclusively in a busy, inner-city ED has taught me that anything that can go wrong will go wrong – injuries, assaults, self-injurious behavior, guns, knives, and even attempted escapes (into the ceiling, no kidding, I’ve seen it twice).

The agitated and violent patient clearly represents a threat to patient and provider safety.  I teach (preach) the underappreciated risk of the “squeaky wheel effect.”  Attention is focused on the behavior, rather than the patient.  What is the underlying pathology in the agitated patient?  Who else is sick in your department?  And finally, who else is coming in sick?  Acute undifferentiated agitation prevents adequate evaluation of the patient at hand, distracts from others already in your care, and inhibits the assessment of new patients.  Agitation management is a priority.

Like airway management, a backup plan is crucial when approaching agitation.  Things to consider when selecting a sedative – degree of agitation, feasible routes of administration, time to medication onset of action, risk of respiratory suppression, risk of hypotension, incidence of arrhythmias (real, and perceived risk of TdP).  EKG’s before sedation has never quite made sense to me.  I’m not sure the patient climbing into the ceiling would have held still long enough.

Olanzapine has filled the void in my practice resulting from the droperidol drug shortage.  Our data suggests that a single 5 mg IV dose of olanzapine will control agitation in approximately two-thirds of patients (where IV access was obtainable).  5 mg IV is a good place to start, but repeat dosing for agitation is common.  In our ED, we are now approved to administer up to two 5-mg doses of olanzapine to patients in a 24-hour period.  I use IV olanzapine in moderately agitated patients, re-dosing if necessary.  In severely agitated patients, I prefer dosing between 10 and 20 mg IM.  I frequently start at 20 mg, the maximum daily dose.  In patients with persistent or extreme agitation, I will follow olanzapine with either haloperidol and/or lorazepam.  Although some have reservations about the combination of benzodiazepines and olanzapine, the reality is that the only significant risk is over sedation.  The benefit of agitation management, the ability to completely assess the patient, and ensuring patient and provider safety far outweigh this risk.  Ultimately, this “complication” can be anticipated, should be monitored for (SaO2, EtCO2 and close observation) and is completely manageable by the intensivist or emergency physician who deals with acute undifferentiated agitation on a regular basis.  In our study, 47 patients received benzodiazepines within 2 hours of IV olanzapine.  Personally, the combination does not make me nervous, but I realize I do not practice in a vacuum.

Truthfully, I’m a believer.  If you think of using olanzapine, you probably should.  The biggest downside is well known, sedation.  The only “poor” candidate for IV (or IM) olanzapine is one that needs to be discharged immediately.  The benefit of using IV olanzapine in this population is that lower doses, 1.25 – 2.5 mg, are very effective with less sedation.  I find it particularly valuable for nausea, vomiting, diarrhea, vertigo and opioid withdrawal.  The onset of action is relatively short for these indications, 5 – 10 minutes.  I can’t say that I have seen significant delays in the elderly, CHF patients or other states where circulation is impaired.  Anecdotally, although very effective, I haven’t felt that 5 mg IV olanzapine is as effective as the 10mg IM dosing for headache we’ve reported previously (5).

Stay tuned for an EMCrit podcast with Scott Weingart and Marc Martel, to discuss sedation, olanzapine, and patients escaping into the ceiling.

Related posts

  • Allergies to haloperidol don't exist (PulmCrit)
  • On human bondage and the art of the chemical takedown (EMCrit)

Conflicts of interest: Neither myself nor Dr. Martel have any.

Notes:
  1. Eventually this patient woke up, her akithisia resolved, and she did fine. However, this event may be regarded as a “near-miss” because she did end up getting slightly oversedated and could potentially have been harmed.
  2. This post focuses on comparing IV haloperidol vs. IV olanzapine, because IV droperidol isn't available to me.
  3. One study involving multiple different doses of olanzapine found that 7.5 mg of IM haloperidol was equivalent to between 2.5-5 mg of IM olanzapine (Breier 2002). Other studies found 7.5 mg haloperidol IM to be less effective than 10 mg olanzapine IM, which may not be very surprising.
  4. At Genius General Hospital, our goal is to get patients better regardless of cost. However, this issue invariably comes up, so this is an answer to it.
  5. Hill CH, Miner JR, Martel ML. Olanzapine versus droperidol for the treatment of primary headache in the emergency department. Academic Emergency Medicine. 2008 Sep 1;15(9):806-11

Picture credits: opening image is from Sharma 1998 showing a telemetry strip from a patient who received IV haloperidol and subsequently developed TdP, with additional image from here.

  • Author
  • Recent Posts
Josh Farkas
Social Me

Josh Farkas

Josh is the creator of PulmCrit.org. He is an associate professor of Pulmonary and Critical Care Medicine at the University of Vermont.
Josh Farkas
Social Me

Latest posts by Josh Farkas (see all)

  • IBCC chapter & cast – Hyponatremia - December 12, 2019
  • PulmCrit- Hyperdiuresis:Using hypertonic saline to facilitate diuresis - December 9, 2019
  • IBCC chapter & cast – Hypokalemia - December 5, 2019

Share this:

  • Facebook
  • Twitter
  • Reddit
  • Pinterest
  • Email
  • Print

Filed Under: PULMCrit


14
Comment Here

avatar
We may delete without a full, true name
Your Job (i.e. intensivist, CCRN, etc.)
10 Comment threads
4 Thread replies
1 Followers
 
Most reacted comment
Hottest comment thread
7 Comment authors
Adam GefvertGlobal Intensive Care | Bark Scorpion Sting: Indications for Anascorp and dosing controversiesDean BurnsJosh FarkasRobert Chasse Recent comment authors
avatar
We may delete without a full, true name
Your Job (i.e. intensivist, CCRN, etc.)
newest oldest most voted
trackback
285. Psychotropic Medications and Rapid Tranquilization – EM Three Sixty Five

[…] Intravenous Olanzapine: Faster than IM Olanzapine, safer than IV haloperidol, Josh Farkas, PulmCrit […]

Vote Up0Vote Down  Reply
3 years ago
trackback
Upset, Angry, Agitated, Confused– Pulling Every Tube and Line: Calming the Storm | CritErEd

[…] the heart.  An alternative therapy that might beneficial is Olanzapine (Zyprexa).  Head over to PulmCrit for an great read on the […]

Vote Up0Vote Down  Reply
3 years ago
David Price
Guest
David Price

I would love to see a comparison between Ziprasidone (Geodon) and Olanzapine. I love ziprasidone from everything from agitation to fibromyalgia to gastroparesis to the “I’m allergic to everything” migraine. From my reading and experience, ziprasidone has less akathisia than haloperidol. Its my solid second line drug for migraine and I can’t remember giving narcs for migraines in last 2 years. I suspect olanzapine would be equally efficacious.

Dave Price, MD
Piedmont Hospital Newnan, Atlanta

Vote Up0Vote Down  Reply
3 years ago
Josh Farkas
Author
Josh Farkas

Ziprasidone does have more effects on QTc than olanzapine. Exactly how much risk of TdP that translates into is unclear (probably not much). However, I would still feel a bit more comfortable giving olanzpine than ziprasidone, especially without knowledge of the patient’s QT, potassium level, etc.

I sorry but I don’t have experience using ziprasidone, or using olanzapine for headache. Maybe Marc Martel could comment on the relative efficacy of these agents for migraine.

Josh

Vote Up0Vote Down  Reply
3 years ago
Marc Martel
Guest
Marc Martel

I think we are all on the same page, the majority of anti-psychotics can be used for a variety of presenting complaints. We have studied olanzapine for “benign” headaches, including migraine. It is extremely efficacious, and my go to drug. I have looked at ziprasidone in the past for agitation (not headache). Clinically, my biggest concern was onset of action, it was more in the 20-10 minute time range. That being said, there is no reason in my mind that it wouldn’t work for headache. Just too slow time to clinical effect in agitated ED patients.

Here is the reference for olanzapine and headache:
Hill, C.H., Miner, J.R. and Martel, M.L., 2008. Olanzapine versus droperidol for the treatment of primary headache in the emergency department. Academic Emergency Medicine, 15(9), pp.806-811.

Best,
Marc

Vote Up0Vote Down  Reply
3 years ago
trackback
LITFL Review 218 | LITFL: Life in the Fast Lane Medical Blog

[…] review on treatment of agitated delirium with IV Olanzapine by Josh Farkas. […]

Vote Up0Vote Down  Reply
3 years ago
Josh Farkas
Author
Josh Farkas

*********Question via e-mail********* Josh- I was happy to see your recent post regarding olanzapine v haldol because it indirectly brought up a question I have been hoping you would tackle for some time. The Qt question. In our ICU (large academic MICU) there is a policy about getting Qts, either on the monitor or on an EKG, for people we order Haldol for. I have been skeptical of this policy for a few reasons. 1. The benefit of safely sedating a critically ill patient, particularly one who is very agitated and either pulling out IVs, taking oxygen off, being violent etc, seems to almost always outweigh the risk of Tdp. You mentioned this in your post, and this goes along with what I have found in the literature, but the true incidence of IV halol induced Tdp appears to be quite small, and seems to have also been seen in larger doses. 2. The alternative to using an antipsychotic (I won’t address the olanzapine idea here because this is the first I’m reading of it and its not available in IM or IV form here) is usually using a benzo, which is probably much more harmful to the patient that… Read more »

Vote Up0Vote Down  Reply
3 years ago
Anton Helman
Guest
Anton Helman

Fantastic post. I wonder what your thoughts are regarding ‘big pharma’ influence on olanzapine studies. I’ve always been skeptical of olanzapine for that reason and the cost. I also tend to rely more on benzodiazepines in agitated patients without obvious psychosis as benzodiazepines are incredibly safe in the non-intubate patient in the acute ED setting.

Vote Up0Vote Down  Reply
3 years ago
Josh Farkas
Author
Josh Farkas

I agree, that is an issue which I’ve considered a lot while working on this post.

The most notable source of big pharma influence was a series of RCTs comparing IM olanzapine vs IM haloperidol. Several of these were actually written directly by employees of Eli Lilly. Some studies did seem to be tilting things in favor of olanzapine (e.g. comparing 10 mg olanzapine vs. 7.5 mg haloperidol, which is very likely to make olanzapine “more effective”). However, there were additional RCTs without conflicts of interest which reached identical conclusions.

The most pivotal clinical studies used in the post are Chan 2013 and Martel 2015, both of which did not have conflicts of interest. The material on TdP risk seems fairly free of bias as well.

On one hand, I don’t want to overlook bias and be duped by big pharma. On the other hand, I don’t want to be overly suspicious and ignore a useful drug. Overall, I think there is enough bias-free evidence to make an argument for olanzapine.

Vote Up0Vote Down  Reply
3 years ago
Robert Chasse
Guest
Robert Chasse

Just to give a historical perspective there was a time in the late 80’s and early 90s that Haldol was given by continuous infusion at astronomical doses for delirium. This was based on work coming out of mass general that gave as much as 960 mg /day of Haldol to post CABG patients.We ran infusions of between 5-40 mg/hr. In that time I saw only one case of torsade at 30mg/hr which responded to cessation of infusion and IV magnesium.

Vote Up0Vote Down  Reply
3 years ago
Josh Farkas
Author
Josh Farkas

Excellent point. The risk of TdP from haloperidol may be overblown. Historically, haloperidol-induced TdP has occurred mostly in patients getting astronomical doses of haloperidol. Still, I think the TdP issue is clinically relevant for three reasons: 1. Regardless of the precise risk of TdP, the FDA and most literature recommend checking EKGs in patients getting haloperidol. So even if the risk is very low, this doesn’t get us off the hook regarding EKG monitoring. 2. I agree that haloperidol by itself is extremely unlikely to cause TdP. However, if inadvertently given to a patient on other QT-prolonging drugs, this could still cause trouble. For example, I’ve seen TdP due to levofloxacin and also due to ondansetron (zofran)… in patients who were also on sotalol. The combination of a fairly safe drug (haloperidol, ondansetron, levofloxacin) with a bad actor like sotalol can precipitate arrhythmia. We don’t always have the time to thoughtfully go through a patient’s med list when they are acutely agitated, so sooner or later we will stumble onto a combination that causes trouble. Pharmacy Joe’s Blog has a nice description of grading the risk of different drugs : http://www.pharmacyjoe.com/how-to-evaluate-qtc-drug-interactions/ 3. The acceptable rate of death due to TdP… Read more »

Vote Up0Vote Down  Reply
3 years ago
Dean Burns
Guest
Dean Burns

Hi Josh

I thoroughly enjoyed reading this post.

In the UK, olanzapine injection is available ‘off licence’ only by special order.
We do have the oro-dispersable tabs. Are you aware of any studies looking at whether the efficacy of the dissolving tabs is comparable to the IV formulation?

Thanks again for this fascinating piece.

Dean

Vote Up0Vote Down  Reply
3 years ago
trackback
Global Intensive Care | Bark Scorpion Sting: Indications for Anascorp and dosing controversies

[…] administered “off-label” in the emergency department (i.e. ondansetron in the ED, PO naloxone, IV olanzapine, ketamine takedown, etc.). The trials that granted the approval of Anascorp evolved to using […]

Vote Up0Vote Down  Reply
3 years ago
Adam Gefvert
Guest
Adam Gefvert

Hello, I am researching IV Olanzapine and would like to speak with Josh Farkas. I tried contacting him on twitter but no response. Can Josh please email me at agefvert@whitediamondresearch.com? Thanks.

Vote Up0Vote Down  Reply
2 years ago

Follow EMCrit Everywhere

Click for More Subscribe Options


Other Stuff

  • Have a great idea for the next podcast? Share it here!
  • Tough Questions. Maybe you have an answer!
  • When you're done listening to the podcast,
    check out these great sites.

Who We Are

We are the EMCrit Project, a team of independent medical bloggers and podcasters joined together by our common love of cutting-edge care, iconoclastic ramblings, and FOAM.

Like Us on Facebook

Like Us on Facebook

Subscribe by Email

EMCrit is a trademark of Metasin LLC. Copyright 2009-. This site represents our opinions only. See our full disclaimer, our privacy policy, commenting policy and here for credits and attribution.

wpDiscuz
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
You are going to send email to

Move Comment